Alexander Stein
Priv.-Doz. Dr. med.
Alexander Stein
  • Facharzt für Innere Medizin und Hämatologie und Onkologie
  • 1.Arbeitsbereich
Sprachen
Deutsch (Muttersprache)
Englisch

Fachgebiete

Tätigkeitsschwerpunkte

Lebenslauf

Mitgliedschaften

Publikationen

Zurück
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
Vor

Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches
Tintelnot J, Stein A
WORLD J GASTROENTERO. 2019;25(29):3920-3928.

Impact of taste and smell training on taste disorders during chemotherapy – TASTE trial
von Grundherr J, Koch B, Grimm D, Salchow J, Valentini L, Hummel T, Bokemeyer C, Stein A, Mann J
CANCER MANAG RES. 2019;11:4493—4504.

Beyond Second-Line Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
Arnold D, Prager G, Quintela A, Stein A, Moreno S, Mounedji N, Taieb J
ANN ONCOL. 2018;29(4):835-856.

Spätfolgen einer Krebsbehandlung im Kindes- und Jugendalter: Eine Herausforderung für die Transitionsmedizin
Gebauer J, Lehnert H, Schmid S, Spix C, Stein A, Langer T
INTERNIST. 2018;59(11):1157-1162.

Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer
Kasper S, Kisro J, Fuchs M, Müller C, Schulz-Abelius A, Karthaus M, Rafiyan M, Stein A
BMC CANCER. 2018;18(1):1124.

Preventing adverse events of chemotherapy by educating patients about the nocebo effect (RENNO study) - study protocol of a randomized controlled trial with gastrointestinal cancer patients
Quidde J, Pan Y, Salm M, Hendi A, Nilsson S, Oechsle K, Stein A, Nestoriuc Y
BMC CANCER. 2018;18(1):916.

Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients
Samsen A, von der Heyde S, Bokemeyer C, David K, Flath B, Graap M, Grebenstein B, Heflik L, Hollburg W, Layer P, von Leitner E, Overkamp F, Saeger W, Schneider S, von Seydewitz C, Stang A, Stein A, Zornig C, Juhl H
ONCOTARGET. 2018;9(78):34794-34809.

Immunotherapy of Colon Cancer
Stein A, Folprecht G
ONCOL RES TREAT. 2018;41(5):282-285.

Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists
Stein A, Markus M, Jörg T, Eray G, Vogel A
CRIT REV ONCOL HEMAT. 2018;130:13-26.

T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker
Akyüz N, Brandt A, Stein A, Schliffke S, Mährle T, Quidde J, Goekkurt E, Loges S, Haalck T, Ford C, Asemissen A, Thiele B, Radloff J, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Binder M
INT J CANCER. 2017;140(11):2535-2544.

AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer
Kripp M, Prasnikar N, Vehling-Kaiser U, Quidde J, Al-Batran S, Stein A, Neben K, Hannig C, Tessen H, Trarbach T, Hinke A, Hofheinz R
ONCOTARGET. 2017;8(62):105061-105071.

Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer
Quidde J, Denne L, Kutscheidt A, Kindler M, Kirsch A, Kripp M, Petersen V, Schulze M, Seraphin J, Tummes D, Arnold D, Stein A
ONCOL RES TREAT. 2017;40(1-2):21-26.

Versorgung von Patienten nach Krebserkrankung im Kindes-, Jugend- oder jungen Erwachsenenalter
Quidde J, Koch B, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A
J Onkol - Z Onkol Fortb. 2017;2017(10):862-866.

Das CARE-for-CAYA-Programm. Präventionskonzept für junge Menschen nach Krebserkrankung
Quidde J, Koch B, Salchow J, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2017;32(06):479-484.

Personalizing Maintenance Therapy in Metastatic Colorectal Cancer
Quidde J, Stein A
Curr Colorectal Cancer Rep. 2017;13(3):205-211.

LBA-007FOLFOX/Bevacizumab +/- Irinotecan in advanced colorectal cancer (AIO) "CHARTA": Final results and multivariate prognostic factor analysis
Schmoll H, Garlipp B, Junghanß C, Leithäuser M, Vogel A, Schaefers M, Kaiser U, Hoeffkes H, Florschütz A, Rüssel J, Kanzler S, Edelmann T, Forstbauer H, Göhler T, Hannig C, Hildebrandt B, Steighardt J, Cygon F, Meinert F, Stein A
ANN ONCOL. 2017;28(suppl_3):.

Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation
Schrader J, Henes F, Perez D, Burdak-Rothkamm S, Stein A, Izbicki J, Lohse A
ANN ONCOL. 2017;28(4):904-905.

Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study
Creutzfeldt A, Suling A, Oechsle K, Mehnert A, Atanackovic D, Kripp M, Arnold D, Stein A, Quidde J
BMC PALLIAT CARE. 2016;15(1):25.

Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®
Gorges T, Stein A, Quidde J, Hauch S, Röck K, Riethdorf S, Joosse S, Pantel K
PLOS ONE. 2016;11(5):e0155126.

A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells
Hvichia G, Parveen Z, Wagner C, Janning M, Quidde J, Stein A, Müller V, Loges S, Neves R, Stoecklein N, Wikman H, Riethdorf S, Pantel K, Gorges T
INT J CANCER. 2016;138(12):2894-904.

A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
Loupakis F, Stein A, Ychou M, Hermann F, Salud A, Österlund P
TARGET ONCOL. 2016;11(3):293-308.

Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature
Quidde J, Azémar M, Bokemeyer C, Arnold D, Stein A
Ther Adv Med Oncol. 2016;8(3):144-52.

Improved nutrition in adolescents and young adults after childhood cancer - INAYA study
Quidde J, von Grundherr J, Koch B, Bokemeyer C, Escherich G, Valentini L, Buchholz D, Schilling G, Stein A
BMC CANCER. 2016;16(1):872.

Multimodale Therapie des lokalisierten Magenkarzinoms
Stein A, Arnold D, Al-Batran S
ONKOLOGE. 2016;22(6):392-399.

Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study
Stein A, Quidde J, Schröder J, Göhler T, Tschechne B, Valdix A, Höffkes H, Schirrmacher-Memmel S, Wohlfarth T, Hinke A, Engelen A, Arnold D
BMC CANCER. 2016;16(1):82.

Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis
Stein A, Schwenke C, Folprecht G, Arnold D
CLIN COLORECTAL CANC. 2016;15(2):e29-39.

Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis
Tachezy M, Gebauer F, Janot M, Uhl W, Zerbi A, Montorsi M, Perinel J, Adham M, Dervenis C, Agalianos C, Malleo G, Maggino L, Stein A, Izbicki J, Bockhorn M
SURGERY. 2016;160(1):136-44.

A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer
Bokemeyer C, Stein A, Ridwelski K, Atanackovic D, Arnold D, Wöll E, Ulrich A, Fischer R, Krüger C, Schuhmacher C
GASTRIC CANCER. 2015;18(4):833-842.

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
Braig F, März M, Schieferdecker A, Schulte A, Voigt M, Stein A, Grob T, Alawi M, Indenbirken D, Kriegs M, Engel E, Vanhoefer U, Grundhoff A, Loges S, Riecken K, Fehse B, Bokemeyer C, Binder M
ONCOTARGET. 2015;6(14):12035-47.

Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2
Farschtschi S, Kollmann P, Dalchow C, Stein A, Mautner V
EUR ARCH OTO-RHINO-L. 2015;272(12):3857-60.

Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen L, Klümpen H, Lohse A, Nashan B, Primrose J, Schrum S, Shannon J, Vettorazzi E, Wege H
BMC CANCER. 2015;15:Art. 564.

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
Stein A, Atanackovic D, Hildebrandt B, Stübs P, Brugger W, Hapke G, Steffens C, Illerhaus G, Bluemner E, Stöhlmacher J, Bokemeyer C
BRIT J CANCER. 2015;113(6):872-7.

Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study
Stein A, Petersen V, Schulze M, Seraphin J, Hoeffkes H, Valdix A, Schroeder J, Herrenberger J, Boxberger F, Leutgeb B, Hinke A, Kutscheidt A, Arnold D
ACTA ONCOL. 2015;54(2):171-8.

73-jährige leber- und nierentransplantierte Patientin mit dumpfen Oberbauchschmerzen und rezidivierendem Nasenbluten
Zinser M, Salzer H, Stein A, von Petersdorff-Campen M, Koops A, Holzhüter J
INTERNIST. 2015;56(5):566-72.

Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice
Burandt E, Schreiber M, Stein A, Minner S, Clauditz T, Bokemeyer C, Jänicke F, Fisch M, Izbicki J, Knecht R, Sauter G, Stahl P
GENE CHROMOSOME CANC. 2014;53(3):228-39.

Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results
Hofheinz R, Petersen V, Kindler M, Schulze M, Seraphin J, Hoeffkes H, Valdix A, Schroeder J, Herrenberger J, Stein A, Hinke A, Arnold D
BMC CANCER. 2014;14:761.

Exercise training in patients with advanced gastrointestinal cancer undergoing palliative chemotherapy: a pilot study
Jensen W, Baumann F, Stein A, Bloch W, Bokemeyer C, de Wit M, Oechsle K
SUPPORT CARE CANCER. 2014;22(7):1797-806.

Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction
Kuehnle M, Attig S, Britten C, Schulze-Bergkamen H, Lordick F, von Wichert G, Thuss-Patience P, Stein A, Schuler M, Bassermann F, Sahin U, Türeci O
CANCER IMMUNOL IMMUN. 2014;63(12):1273-84.

Survivorship-Programme: Ziele und Inhalte einer strukturierten Betreuung
Schilling G, Stein A, Quidde J, Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;3(29):202-205.

Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection
Schmoll H, Stein A
NAT REV CLIN ONCOL. 2014;11(2):79-80.

Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study
Stein A, Arnold D, Thuss-Patience P, Moehler M, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz R, Schmoll H
ACTA ONCOL. 2014;53(3):392-8.

How to select the optimal treatment for first line metastatic colorectal cancer
Stein A, Bokemeyer C
WORLD J GASTROENTERO. 2014;20(4):899-907.

Neue Substanzen für die Therapie solider Tumoren
Stein A, Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29:300-4.

Antiangiogenese-Therapie beim kolorektalen Karzinom
Arnold D, Stein A
Onkologie heute. 2013;32-35.

Epidemiologische Daten und aktuelle Therapiekonzepte des kolorektalen Karzinoms
Arnold D, Stein A
2013. Zielgerichtete Therapie des kolorektalen Karzinoms. Uni-Med, .

New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy
Arnold D, Stein A
DRUGS. 2013;73(9):883-91.

Cancer patients and advance directives: a survey of patients in a hematology and oncology outpatient clinic
Hubert E, Schulte N, Belle S, Gerhardt A, Merx K, Hofmann W, Stein A, Burkholder I, Hofheinz R, Kripp M
ONKOLOGIE. 2013;36(7-8):398-402.

Oxaliplatin: Clinical Use in Cancer Patients
Stein A
2013. Encyclopedia of Metalloproteins. Springer Science+Business Media, .

Prolonging Survival Through a Personalized Approach in Metastatic Colorectal Cancer
Stein A, Bokemeyer C
J OncoPathol. 2013;1(3):31-41.

Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial
Stein A, Kretzschmar A, Behringer D, Wolff T, Zimber J, Hegewisch-Becker S, Kettner E, Pflüger K, Kirsch A, Arnold D
BMC CANCER. 2013;13:454.

Oxaliplatin for colorectal cancer: recent evidence from clinical trials
Stein A, Quidde J, Arnold D
Colorectal Cancer. 2013;135-44.

Optimum Duration of Metastatic Colorectal Cancer Treatment
Stein A, Schmoll H
Curr Colorectal Cancer Rep. 2013;9(3):223-29.

Systemic treatment of liver metastases from colorectal cancer
Stein A, Schmoll H
Ther Adv Med Oncol. 2013;5(3):193-203.

Current challenges in personalized treatment for colorectal cancer
Arnold D, Stein A
Colorec Cancer. 2012;1(3):185-188.

Personalized treatment of colorectal cancer.
Arnold D, Stein A
ONKOLOGIE. 2012;35 Suppl 1:42-48.

Clinical management of localized colon cancer with capecitabine.
Quidde J, Arnold D, Stein A
Clin Med Insights Oncol. 2012;6:363-373.

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.
Schmoll H, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde C, Balmana J, Regula J, Nagtegaal I, Beets-Tan R, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne C, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard J, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A
ANN ONCOL. 2012;23(10):2479-2516.

Oxaliplatin: a review of approved uses.
Stein A, Arnold D
EXPERT OPIN PHARMACO. 2012;13(1):125-137.

Kolorektale Tumoren: Individualisierte Therapiestrategien
Stein A, Bokemeyer C
Der Allgemeinarzt. 2012;34(20):38-41.

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature
Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, Hollerbach S, Illerhaus G, Königsrainer A, Richter M, Schlitt H, Schmoll H
BMC CANCER. 2012;12:356.

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, Hollerbach S, Illerhaus G, Königsrainer A, Richter M, Schlitt H, Schmoll H
BMC CANCER. 2012;12:356.

Administration of chemotherapy by an arteriovenous fistula in a patient with metastatic rectal cancer after life-threatening, port thrombosis-associated cava superior syndrome. An option for patients without possibility of peripheral or central venous access.
Stein A, Hiemer S, Jordan K, Arnold D, Schmoll H
ONKOLOGIE. 2012;35(7-8):440-442.

Targeting Epithelial Growth Factor Receptor (EGFR) With Cetuximab in Combination With Irinotecan as Salvage Treatment in Refractory Gastric Cancer Patients: A Retrospective Analysis and Review of the Literature
Stein A, Peinert S, Al-Batran S, Arnold D
Eur J Clin Med Oncol. 2012;4(1):11-17.

How to Achieve Long-Term Survival in Patients with Metastatic Rectal Cancer?
Stein A, Schmoll H
2012. Multidisciplinary Management of Rectal Cancer. Springer Berlin Heidelberg: 205-216.

Adjuvant Therapy After Liver Resection for Colorectal Cancer Metastasis: What is the Evidence?
Arnold D, Stein A
Curr Colorec Cancer Rep. 2011;7(2):180-186.

The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll H
BONE MARROW TRANSPL. 2011;46(6):784-789.

Inflammatory lesions of the peritoneum mimic carcinomatosis after treatment with intravenous chemotherapy and intraperitoneal catumaxomab.
Rüssel J, Stein A, Behrmann C, Hauptmann S, Krummenerl P, Schmoll H, Arnold D
J CLIN ONCOL. 2011;29(22):644-646.

Kolorektales Karzinom: Innovationen bei den multimodalen Therapien
Stein A, Arnold D
Deut Arzteblatt. 2011;111(6):.

Multimodale Therapiestrategien bei Lebermetastasen kolorektaler Karzinome
Stein A, Arnold D
Viszeralmedizin. 2011;27(6):437-444.

Current standards and new trends in the primary treatment of colorectal cancer.
Stein A, Atanackovic D, Bokemeyer C
EUR J CANCER. 2011;47 Suppl 3:312-314.

Adjuvant Therapy for Early Colon Cancer: Current Status.
Stein A, Hiemer S, Schmoll H
DRUGS. 2011;71(17):2257-2275.

Letzte Aktualisierung aus dem FIS: 06.12.2019 - 00:37 Uhr